ARS Pharmaceuticals Inc (SPRY) saw its stock soar 5.07% in Wednesday's intraday trading session, outperforming the broader market. This surge comes after the company announced the planned launch of its "neffyinSchools" program in January 2025.
The neffyinSchools program aims to provide eligible public and private K-12 schools in the U.S. with free doses of neffy, ARS Pharmaceuticals' recently approved needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, including anaphylaxis. Each participating school will receive two cartons (four single-use doses) of neffy 2mg for adults and children weighing over 66 lbs.
This initiative is expected to drive wider adoption and usage of neffy in schools across the country, potentially saving lives by ensuring prompt access to epinephrine in cases of severe allergic reactions. Investors appear to view the neffyinSchools program as a positive development that could expand neffy's market reach and boost future sales growth for ARS Pharmaceuticals.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。